FRLN
- Freeline Therapeutics Holdings plc
()
Overview
Company Summary
Freeline Therapeutics Holdings plc (FRLN) is a biopharmaceutical company focused on the development and commercialization of gene therapies for the treatment of severe genetic diseases. The company utilizes cutting-edge technologies to deliver functional genes directly to target cells in order to correct the genetic defects causing these diseases.
Freeline Therapeutics has a unique platform called AAV (adeno-associated virus) gene therapy, which is designed to provide long-term and potentially curative therapies for patients. The company's approach involves using harmless viral vectors to safely transport the functional genes into the patient's cells, with the goal of restoring normal function and halting or reversing the progression of the disease.
The company's pipeline includes potential treatments for various genetic disorders, such as Hemophilia B, Fabry disease, Gaucher disease, and Wilson disease. These conditions are caused by specific genetic mutations, and Freeline Therapeutics aims to develop gene therapies that can effectively address each condition.
In addition to its research and development efforts, Freeline Therapeutics also engages in partnerships and collaborations with other pharmaceutical companies, academic institutions, and research organizations. These collaborations enable the company to leverage the expertise and resources of various stakeholders in advancing its gene therapy platform and expanding its pipeline of potential treatments.
Overall, Freeline Therapeutics Holdings plc focuses on harnessing the power of gene therapy to develop innovative and transformative treatments for severe genetic diseases, with the ultimate aim of improving patients' lives and reducing the burden of these disorders on individuals, families, and healthcare systems.